Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma

• Published in: Scientific reports Vol. 13; no. 1; p. 20567
• Main Authors: Prosz, Aurel, Duan, Haohui, Tisza, Viktoria, Sahgal, Pranshu, Topka, Sabine, Klus, Gregory T., Börcsök, Judit, Sztupinszki, Zsofia, Hanlon, Timothy, Diossy, Miklos, Vizkeleti, Laura, Stormoen, Dag Rune, Csabai, Istvan, Pappot, Helle, Vijai, Joseph, Offit, Kenneth, Ried, Thomas, Sethi, Nilay, Mouw, Kent W., Spisak, Sandor, Pathania, Shailja, Szallasi, Zoltan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 23.11.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/114; 631/114/2413; 631/67; 631/67/589/1588; 631/67/69; 692/308; 692/4017; Antitumor agents; Biopsy; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - genetics; Clear cell-type renal cell carcinoma; Deoxyribonucleic acid; DNA; DNA Damage; DNA Repair; Humanities and Social Sciences; Humans; Inactivation; Kidney cancer; Kidney Neoplasms - drug therapy; Kidney Neoplasms - genetics; Lethality; multidisciplinary; Next-generation sequencing; Nucleotide excision repair; Science; Science (multidisciplinary); Sesquiterpenes; Ultraviolet Rays; Xeroderma Pigmentosum Group D Protein - genetics

Due to a demonstrated lack of DNA repair deficiencies, clear cell renal cell carcinoma (ccRCC) has not benefitted from targeted synthetic lethality-based therapies. We investigated whether nucleotide excision repair (NER) deficiency is present in an identifiable subset of ccRCC cases that would rend...